Tens of thousands of malaria patients die each year because the healthcare delivery systems in African nations only reach part of the population and are often deficient, and procurement procedures take far too long. Effective malaria drugs such as Novartis’ Coartem and Coartem Dispersible are available at a low price for the public sector, but unfortunately countries do not always ensure these treatments are accessible to patients. Novartis wants to drive access for patients to life-saving therapy and has the capacity to provide 100 million Coartem treatments per year if orders are placed in a timely manner. This capacity was never fully used last year... To further access, Novartis has recently reduced the public sector price...